UNITED THERAPEUTICS CORP (UTHR)
XMEX XMEX Primary Summary
UTHR Chart
UNITED THERAPEUTICS CORP (UTHR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has UNITED THERAPEUTICS CORP ever had a stock split?
UNITED THERAPEUTICS CORP Profile
| - Industry | - Sector | Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. CEO | XMEX Exchange | - ISIN |
| United States Country | 1,305 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
United Therapeutics Corporation stands as a pioneering entity in the biotech sector, dedicated to crafting innovative solutions to fill the void in medical care for patients grappling with chronic and life-threatening conditions globally. Since its inception in 1996, with its headquarters in Silver Spring, Maryland, the company has emerged as a leader in addressing the complex needs of these patients through the development and commercialization of a range of therapeutic products and technologies. The company has established itself as a significant player in the US and international markets, reflecting its commitment to improving the quality of life and extending the survival of patients facing serious health challenges.
Products and Services
United Therapeutics Corporation’s portfolio encompasses a diverse array of products aimed at tackling pulmonary arterial hypertension (PAH) and other severe diseases, through innovative methods and formulations: - Tyvaso DPI: This product represents a novel approach in the administration of medication, offering an inhaled dry powder dispensed through pre-filled, single-use cartridges, catering to the convenience and compliance of patients. - Tyvaso: Similar in therapeutic target to Tyvaso DPI, Tyvaso is another form of inhaled treatment but is delivered using an ultrasonic nebulizer, providing an alternative means of administration for patients. - Remodulin (treprostinil) injection: Serving as a cornerstone treatment option, Remodulin is designed specifically for PAH patients. Administered as an injection, it aims to reduce symptoms associated with physical activity, offering hope and improved quality of life. - Orenitram: Orenitram, a tablet formulation of treprostinil, takes on PAH with a focus on delaying disease progression and enhancing exercise capacity, representing a critical step forward in oral treatment options. - Adcirca: An oral PDE-5 inhibitor, Adcirca is designed to better the exercise capabilities of PAH patients, widening the scope of treatments available within United Therapeutics’ portfolio. - Unituxin (dinutuximab) injection: Venturing beyond PAH, Unituxin addresses high-risk neuroblastoma in children. This monoclonal antibody injection marks a significant advancement in pediatric oncology. - Remunity Pump: For the continuous delivery of Remodulin, the Remunity Pump combines a pump with a separate controller, innovating the way medication is administered and monitored. Additionally, United Therapeutics is actively engaged in groundbreaking research and development efforts, aiming to bring forth new solutions for PAH and other diseases. This includes initiatives like RemoPro and Ralinepag for PAH treatment, Aurora-GT for gene therapy, Nebulized Tyvaso targeting idiopathic pulmonary fibrosis, and development-stage organ xenografts. Collaborative ventures with DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc., further underscore the company's commitment to innovation and expanding its therapeutic arsenal.
